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Abstract
Together with biliary drainage, which is an appropriate proce-
dure for unresectable biliary cancer, biliary stent placement is 
used to improve symptoms associated with jaundice. Owing to 
investigations comparing percutaneous transhepatic biliary 
drainage (PTBD), surgical drainage, and endoscopic drainage, 
many types of stents are now available that can be placed 
endoscopically. The stents used are classiﬁ  ed roughly as plastic 
stents and metal stents. Compared with plastic stents, metal 
stents are of large diameter, and have long-term patency 
(although they are expensive). For this reason, the use of 
metal stents is preferred for patients who are expected to 
survive for more than 6 months, whereas for patients who are 
likely to survive for less than 6 months, the use of plastic stents 
is not considered to be improper. Obstruction in a metal stent 
is caused by a tumor that grows within the stent through the 
mesh interstices. To overcome such problems, a covered metal 
stent was developed, and these stents are now used in patients 
with malignant distal biliary obstruction. However, this type 
of stent has been reported to have several shortcomings, such 
as being associated with the development of acute cholecysti-
tis and stent migration. In spite of these shortcomings, evi-
dence is expected to demonstrate its superiority over other 
types of stent.
Key words Biliary stenting · Biliary tract cancer · Obstructive 
jaundice · Guidelines
Introduction
More than 20 years have passed since stents began to 
be used for treating unresectable bile duct stricture in 
patients with obstructive jaundice. Previously, percuta-
neous transhepatic cholangial drainage (PTCD); also 
known as percutaneous transhepatic biliary drainage 
(PTBD) was employed for patients with this disease, 
and the patients were often forced to stay in hospital for 
a long period of time with an external biliary ﬁ  stula. The 
creation of an internal ﬁ  stula is now widely used because 
it is as useful as surgical bypass in improving not only 
quality of life (QOL) but also survival rates. Today, non-
invasive endoscopic stent placement is being used for 
most patients with this disease as an alternative proce-
dure to the percutaneous approach. Plastic stents (PS), 
which have been used until now, are economical, but 
their shortcoming is that they give rise to obstruction at 
an earlier stage, so several improvements have been 
made. On the other hand, metal stents (MS), in which 
the insertion of the stents is enabled with a slender 
delivery system and the stents expand to a large diam-
eter by themselves, have conferred noticeably extended 
patency compared with PS. However, their shortcom-
ings are that they are more expensive than PS and 
replacing them is difﬁ  cult once they have been placed.
Here we pose clinical questions (CQs) regarding 
stenting for obstructive jaundice in patients with un-
resectable biliary carcinoma, with responses in the form 
of recommendations (grades of the recommendations 
are deﬁ  ned in Table 1
1). Also, levels of evidence are 
given (in parentheses) for ﬁ  ndings in reference citations 
(see deﬁ  nitions of levels in Table 2
1).
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Biliary drainage should be performed 
(recommendation B).
There are many studies reporting the approach route of 
drainage for unresectable malignant distal biliary 
obstruction, methods of stenting, and the quality of stent 
materials. In view of this situation, it is thought that the 
relief of jaundice should be conducted as a matter of 
CQ 1 Is biliary drainage recommended for patients 
with unresectable disease?
Table 3.  Prospective and randomized controlled trials for plastic versus metal stents in the palliative treatment of distal malignant 
biliary obstruction
6–11,20
Reference
Stent 
group
No. of 
patients
Stent 
occlusion P
Stent patency
(months) P
Median survival
(months) P
Davids et al.,
6 
1992
MS 49 16 NR 9.1 0.006 5.8 0.45
PS 56 30 4.2 4.9
Knyrim et al.,
7 
1993
MS 31  6 NR 6.2 NR  NR NR
PS 31 10 4.6 NR
Prat et al.,
8 1998 MS 34 NR NR 4.8 <0.05
e 4.5 NS
PS
a 34 NR 3.2 5.6
PS
b 33 NR 3.2 4.8
Kaassis et al.,
9 
2003
MS 59 11 <0.007 NR 0.007 5.1 NS
PS 59 22 5.5 3.3
Katsinelos et al.,
10 
2006
MS 23 23 NS 8.5 0.002 9.1 NS
PS
c 24 24 4.1 6.9
Soderlund et al.,
11 
2006
MS
d 49  9 0.009 3.6 0.002 5.3 0.27
PS 51 22 1.8 3.9 76
MS, metal stent; PS, plastic stent; NR, not reported; NS, not signiﬁ  cant
a Stent exchanged every 3 months with or without evidence of stent dysfunction
b Stent exchanged on evidence of stent dysfunction
c Tannenbaum stent
d Covered MS
e MS versus PS
a and PS
b
course. Also, the creation of an internal ﬁ  stula, where 
possible, is recommended.
For the drainage route, there are reports of random-
ized controlled trials (RCTs)
2,3  (level II) comparing 
endoscopic drainage, PTBD, and surgical drainage. The 
success rate for the creation of an internal ﬁ  stula is 
reported to be 95%–100%
4,5 (levels II, IV). According 
to these reports, endoscopic drainage is preferable to 
the other two methods. A metaanalysis showed that 
endoscopic drainage was associated with a lower risk of 
complications, but a higher risk of recurrent biliary 
obstruction than surgical drainage
4 (level II). The per-
cutaneous procedure is performed in patients in whom 
the endoscopic procedure has been unsuccessful.
Concerning the types of stent available, there are 
several RCTs suggesting the superiority of metal stents 
over plastic stents with respect to stent patency
4–12 (level 
II).
For hepatic hilar bile duct stricture, placement of mul-
tiple stents has been reported to confer better drainage 
effects than those brought about by single-stent place-
ment
13 (level IV), although there are also prospective 
trials demonstrating that single stents are as effective as 
Table 1.  Strength of recommendations
1
A, Strongly recommend performing the clinical action
B, Recommend performing the clinical action
C1, The clinical action may be considered although there is a 
lack of high-level scientiﬁ  c evidence for its use. May be 
useful
C2, Clinical action not deﬁ  nitively recommended because of 
insufﬁ  cient scientiﬁ  c evidence. Evidence insufﬁ  cient to 
support or deny usefulness
D, Recommend not performing the clinical action
Table 2.  Levels of evidence
1
Level I Systematic review/meta-analysis
Level II One or more randomized clinical trials
Level III Nonrandomized controlled trials
Level IV Analytic epidemiology (cohort studies and case-control studies)
Level V Descriptive study (case reports and case-series studies)
Level VI Opinions of expert panels and individual experts not based on 
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including hospitalization expenses, is thought to be 
lower compared with that of plastic stents because of 
the reduced frequency of re-intervention.
6,7 According 
to recent reports, the cost of plastic stents is low for the 
reasons that, in patients for whom prognosis is poor, 
long-term survival is not expected (patients with liver 
metastasis) and re-intervention is also unnecessary.
8–10 
In patients for whom long-term survival exceeding 6 
months is expected, metal stents may be used from the 
initial intervention, while in patients for whom survival 
exceeding 6 months is not expected, similar results are 
achieved by using plastic stents (level IV).
In metal stents, which are made of mesh materials, 
obstruction due to the ingrowth of tumors has often 
occurred. To cope with this problem, polyurethane–
covered metal stents have become available in clinical 
settings (Fig. 2)
21 (level IV), and their superior patency 
has been demonstrated by an RCT
22 (level II). Recent 
case series studies, however, reported that no signiﬁ  cant 
difference in patency rate was found between covered 
and uncovered metal stents, because covered metal 
stents have several drawbacks, such as stent-migration 
and the occurrence of acute cholecystitis
23–25 (level IV). 
Furthermore patients with pancreatic cancer have been 
included in the results of studies of stent treatment for 
malignant distal biliary stricture. Accumulation of evi-
dence is awaited.
There is much controversy as to the importance of 
establishing drainage of both liver lobes in malignant 
hilar biliary obstruction. Drainage with a unilateral 
uncovered metal stent is reported to be effective for 
hilar biliary obstruction
15,26,27  (level III, IV); however, 
there are no RCTs regarding unilateral or bilateral 
metal stent drainage. Concerning plastic stents, an RCT 
failed to ﬁ  nd any difference in drainage effects between 
single stents and multiple stents
15 (level II). Although 
an RCT
12 (level II) regarding plastic stents and metal 
stents showed that both success and patency rates were 
better for metal stents than for plastic stents, the RCT 
Fig. 1.  Plastic stents. From left, plastic stents with outer diam-
eters of 10, 8.5, and 7 Fr, are shown
Fig.  2.  Covered metal stent (Wallstent; Boston Scientiﬁ  c, 
Natick, MA, USA). This metal stent is partially covered
CQ 2 Which type of biliary stent is appropriate for 
unresectable cases?
A metal stent is preferable in view of stent patency 
(recommendation C1).
Plastic stents with an outer diameter of 8–10 Fr are now 
in use (Fig. 1). These are easily clogged, so stents with a 
larger diameter have occasionally been employed in the 
past. However, due to the pain and technical difﬁ  culties 
accompanying the insertion of these stents, they have 
fallen into disuse. Improvements have been made in the 
quality of materials and the shape of stents, but no dif-
ference in patency rates has been observed
16–19 (level 
II).
There are RCTs comparing plastic stents with metal 
stents in the palliative treatment of distal malignant 
biliary obstruction
4–11  (level II). As for the median 
patency of stents, metal stents (3.6–9.1 months) are sig-
niﬁ  cantly superior to plastic stents (1.8–5.5 months), but 
no difference was found in median survival (Table 3).
20 
Although metal stents are expensive, their overall cost, 
multiple stents
14,15  (levels II, III). However, there are 
several questions as to hepatic hilar bile duct stricture, 
such as the presence of segments for which drainage is 
unable to be achieved and the clogging of stents, so stent 
placement in these patients is still controversial.72  T. Tsuyuguchi et al.: Stenting for malignant biliary obstruction
included only 20 patients with hilar biliary obstruction. 
Hence, it is still controversial which type of stents 
should be used in patients with hilar biliary 
obstruction.
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